Abstract:Background: Bone morphogenetic proteins (BMPs) have been reported to maintain epithelial integrity and to antagonize the transforming growth factor β (TGFβ)-induced epithelial to mesenchymal transition. The expression of soluble BMP antagonists is dysregulated in cancers and interrupts proper BMP signaling in breast cancer. Methods: In this study, we mined the prognostic role of BMP antagonists GREMLIN 1 (GREM1) in primary breast cancer tissues using in-house and publicly available datasets. We determined which cells express GREM1 RNA using in situ hybridization (ISH) on a breast cancer tissue microarray. The effects of Grem1 on the properties of breast cancer cells were assessed by measuring the mesenchymal/stem cell marker expression and functional cell-based assays for stemness and invasion. The role of Grem1 in breast cancer-associated fibroblast (CAF) activation was measured by analyzing the expression of fibroblast markers, phalloidin staining, and collagen contraction assays. The role of Grem1 in CAF-induced breast cancer cell intravasation and extravasation was studied by utilizing xenograft zebrafish breast cancer (co-) injection models. Results: Expression analysis of clinical breast cancer datasets revealed that high expression of GREM1 in breast cancer stroma is correlated with a poor prognosis regardless of the molecular subtype. The large majority of human breast cancer cell lines did not express GREM1 in vitro, but breast CAFs did express GREM1 both in vitro and in vivo. Transforming growth factor β (TGFβ) secreted by breast cancer cells, and also inflammatory cytokines, stimulated GREM1 expression in CAFs. Grem1 abrogated bone morphogenetic protein (BMP)/SMAD signaling in breast cancer cells and promoted their mesenchymal phenotype, stemness, and invasion. Moreover, Grem1 production by CAFs strongly promoted the fibrogenic activation of CAFs and promoted breast cancer cell intravasation and extravasation in co-injection xenograft zebrafish models. Conclusions: Our results demonstrated that Grem1 is a pivotal factor in the reciprocal interplay between breast cancer cells and CAFs, which promotes cancer cell invasion. Targeting Grem1 could be beneficial in the treatment of breast cancer patients with high Grem1 expression.

Recent progress in Gremlin

Gremlin1: a BMP antagonist with therapeutic potential in Oncology

Tgf-Beta and Bmp Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease

Current status and prospects of GREM1 research in cancer (Review)

Secreted BMP Antagonists and Their Role in Cancer and Bone Metastases.

Gremlin2 Activates Fibroblasts to Promote Pulmonary Fibrosis Through the Bone Morphogenic Protein Pathway

Gremlin 1 Identifies a Skeletal Stem Cell with Bone, Cartilage, and Reticular Stromal Potential.

Vital Roles of Gremlin‐1 in Pulmonary Arterial Hypertension Induced by Systemic‐to‐Pulmonary Shunts

Gremlin1 plays a key role in kidney development and renal fibrosis

Gremlin is Overexpressed in Lung Adenocarcinoma and Increases Cell Growth and Proliferation in Normal Lung Cells

Gremlin is a Key Pro-Fibrogenic Factor in Chronic Pancreatitis

GREM1 Negatively Regulates Osteo-/Dentinogenic Differentiation of Dental Pulp Stem Cells via Association with YWHAH

The possible role of Gremlin1 in inflammatory apical periodontitis

GREM1 Signaling in Cancer: Tumor Promotor and Suppressor?

The Expression of Glia Maturation Factors and the Effect of Glia Maturation Factor-Γ on Angiogenic Sprouting in Zebrafish

[Current Progress in Functions of Axon Guidance Molecule Robo and Underlying Molecular Mechanism].

Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression

Angiogenic and Fibrogenic Dual-effect of Gremlin1 on Proliferative Diabetic Retinopathy

Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis

Gremlin-2 is a novel tumor suppressor that negatively regulates ID1 in breast cancer

GREM1 is Associated with Metastasis and Predicts Poor Prognosis in ER-negative Breast Cancer Patients